Myelofibrosis, Primary, Myelofibrosis, Post PV, Myelofibrosis, Post ET
Conditions
Brief summary
The aim of the study is to determine the rate of HMR mutations in PMF and secondary MF (post PV/ET) subjects, and correlate the rate of mutations with clinical features as known prognostic scores.
Detailed description
Main inclusion criteria: 1. Diagnosis of PMF, post PV MF or post ET MF according to the WHO 2008 classification 2. Age ≥ 18 years 3. Concurrent participation in clinical trials will be allowed. Efficacy assessments will be evaluated by: HMR mutations rate, specific HMR mutations, disease duration, presence of splenomegaly, cytogenetic risk, DIPPS, IPSS, ET survival score and PV survival score. The primary efficacy parameter to be assessed will be HMR mutation rate.
Interventions
OTHERMolecular analysis
Blood test
Sponsors
Assaf-Harofeh Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of PMF, post PV MF or post ET MF according to the WHO 2008 classification 2. Age . 18 years 3. Patient is willing and capable of giving a written informed consent. 4. Concurrent participation in clinical trials will be allowed
Exclusion criteria
1. Unwilling or unable to provide informed consent 2. Prefibrotic MF
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of patients with one or more HMR mutations in primary compared to secondary (post PV/ET) MF | Baseline | Proportions of patients with HMR mutations in each arm |
Countries
Israel
Contacts
Primary ContactShirly Broitman
Outcome results
None listed